David Lebowitz
Stock Analyst at Citigroup
(2.21)
# 1,421
Out of 4,502 analysts
70
Total ratings
42.55%
Success rate
-3.01%
Average return
Main Sectors:
20 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $38 → $64 | $40.37 | +58.53% | 3 | Jun 18, 2024 | |
| PTCT PTC Therapeutics | Maintains: Sell | $18 → $26 | $33.57 | -22.55% | 2 | May 21, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $31 → $29 | $26.42 | +9.77% | 3 | May 10, 2024 | |
| PLRX Pliant Therapeutics | Maintains: Buy | $45 → $44 | $13.31 | +230.58% | 4 | May 7, 2024 | |
| BPMC Blueprint Medicines | Maintains: Sell | $65 → $76 | $113.69 | -33.15% | 5 | May 3, 2024 | |
| SDGR Schrödinger | Maintains: Buy | $39 → $37 | $22.29 | +65.99% | 7 | May 2, 2024 | |
| MDGL Madrigal Pharmaceuticals | Initiates: Buy | $382 | $283.46 | +34.76% | 1 | Mar 6, 2024 | |
| COGT Cogent Biosciences | Maintains: Buy | $11 → $13 | $9.22 | +41.00% | 2 | Feb 26, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $42 → $46 | $26.70 | +72.28% | 2 | Feb 23, 2024 | |
| INCY Incyte | Maintains: Buy | $82 → $81 | $68.57 | +18.13% | 2 | Feb 14, 2024 | |
| ASND Ascendis Pharma | Maintains: Buy | $146 → $182 | $134.38 | +35.44% | 9 | Feb 8, 2024 | |
| EXEL Exelixis | Initiates: Buy | $31 | $22.96 | +35.02% | 1 | Dec 15, 2023 | |
| IONS Ionis Pharmaceuticals | Upgrades: Buy | $36 → $60 | $51.86 | +15.70% | 8 | Jul 31, 2023 | |
| BMRN BioMarin Pharmaceutical | Maintains: Neutral | $103 → $96 | $85.59 | +12.16% | 3 | Jun 30, 2023 | |
| IMRX Immuneering | Maintains: Equal-Weight | $18 → $12 | $1.23 | +875.61% | 2 | Jul 15, 2022 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $170 → $164 | $237.88 | -31.06% | 6 | Jul 15, 2022 | |
| ARQT Arcutis Biotherapeutics | Maintains: Overweight | $36 → $39 | $10.10 | +286.14% | 6 | Jun 7, 2022 | |
| SNDX Syndax Pharmaceuticals | Maintains: Equal-Weight | n/a | $24.63 | - | 1 | Oct 12, 2021 | |
| KPTI Karyopharm Therapeutics | Maintains: Overweight | n/a | $0.96 | - | 1 | Oct 12, 2021 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Equal-Weight | n/a | $6.79 | - | 2 | Oct 12, 2021 |
Mirum Pharmaceuticals
Jun 18, 2024
Maintains: Buy
Price Target: $38 → $64
Current: $40.37
Upside: +58.53%
PTC Therapeutics
May 21, 2024
Maintains: Sell
Price Target: $18 → $26
Current: $33.57
Upside: -22.55%
Intellia Therapeutics
May 10, 2024
Maintains: Neutral
Price Target: $31 → $29
Current: $26.42
Upside: +9.77%
Pliant Therapeutics
May 7, 2024
Maintains: Buy
Price Target: $45 → $44
Current: $13.31
Upside: +230.58%
Blueprint Medicines
May 3, 2024
Maintains: Sell
Price Target: $65 → $76
Current: $113.69
Upside: -33.15%
Schrödinger
May 2, 2024
Maintains: Buy
Price Target: $39 → $37
Current: $22.29
Upside: +65.99%
Madrigal Pharmaceuticals
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $283.46
Upside: +34.76%
Cogent Biosciences
Feb 26, 2024
Maintains: Buy
Price Target: $11 → $13
Current: $9.22
Upside: +41.00%
BridgeBio Pharma
Feb 23, 2024
Maintains: Buy
Price Target: $42 → $46
Current: $26.70
Upside: +72.28%
Incyte
Feb 14, 2024
Maintains: Buy
Price Target: $82 → $81
Current: $68.57
Upside: +18.13%
Ascendis Pharma
Feb 8, 2024
Maintains: Buy
Price Target: $146 → $182
Current: $134.38
Upside: +35.44%
Exelixis
Dec 15, 2023
Initiates: Buy
Price Target: $31
Current: $22.96
Upside: +35.02%
Ionis Pharmaceuticals
Jul 31, 2023
Upgrades: Buy
Price Target: $36 → $60
Current: $51.86
Upside: +15.70%
BioMarin Pharmaceutical
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $85.59
Upside: +12.16%
Immuneering
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $1.23
Upside: +875.61%
Alnylam Pharmaceuticals
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $237.88
Upside: -31.06%
Arcutis Biotherapeutics
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $10.10
Upside: +286.14%
Syndax Pharmaceuticals
Oct 12, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $24.63
Upside: -
Karyopharm Therapeutics
Oct 12, 2021
Maintains: Overweight
Price Target: n/a
Current: $0.96
Upside: -
Ironwood Pharmaceuticals
Oct 12, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $6.79
Upside: -